Opaganib Completed Phase 2 Trials for Non-Resectable Cholangiocarcinoma / Intrahepatic Cholangiocarcinoma / Perihilar Cholangiocarcinoma / Extrahepatic Cholangiocarcinoma / Cholangiocarcinoma Treatment

Indications	Status	Purpose	Phase
DBCOND0076365 (Non-Resectable Cholangiocarcinoma) DBCOND0051753 (Intrahepatic Cholangiocarcinoma) DBCOND0132554 (Perihilar Cholangiocarcinoma) DBCOND0069928 (Extrahepatic Cholangiocarcinoma) DBCOND0012992 (Cholangiocarcinoma)	Completed	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT03377179	A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma	Hydroxychloroquine (DB01611) Opaganib (DB12764)